Skip to Main Content

Paper Details

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
J Clin Oncol
23
2023
Author NameAffiliation
Emmanuel S AntonarakisJohns Hopkins Sidney Kimmel Comprehensive Cancer Center
Emmanuel S AntonarakisCurrent Address: University of Minnesota Masonic Cancer Center
Niven MehraRadboud University Medical Center
Evan Y YuFred Hutchinson Cancer Center, University of Washington
  • 1 - 4

Datasets

Release 1.2